A Study of HNC664 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics

NCT04504448 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: HNC664 capsules Single dose
DRUG: HNC664 placebos Single dose
DRUG: HNC664 capsules FED

Sponsor

Guangzhou Henovcom Bioscience Co. Ltd.